1. Introduction {#s0005}
===============

Surveillance, Epidemiology and End Results Program (SEER) from the National Cancer Institute estimates approximately 22, 440 new cases of ovarian cancer per year. However, the ovary is a common site for metastasis with approximately 15% of ovarian cancers noted to be secondary malignancies ([@bb0145]). Metastases most commonly arise from the colon, breast, uterus and stomach. Their clinical and histological features often mimic those of primary ovarian neoplasms, especially in endometrioid and mucinous type neoplasms.

Approximately 5--10% of primary epithelial ovarian cancers are reportedly mucinous adenocarcinomas. However more recent literature acknowledges that this may be an overestimate, as many "primaries" are actually undiagnosed metastases from the gastrointestinal (GI) tract ([@bb0170]). The most common primary sites of the GI tract that give rise to metastatic mucinous carcinoma within the ovary are colon/rectum, appendix, pancreas, biliary tract, and stomach. Distinction of primary versus secondary ovarian neoplasms can be especially difficult when a patient presents with metastatic disease. In a review by Petru et al., researchers reported that ovarian involvement may precede detection of the primary neoplasm in up to 38% of cases ([@bb0160]).

Ovarian metastases from the GI tract have been well-studied, the notorious example being the Krukenberg tumor. This tumor most commonly arises from the stomach and is defined by the histological identification of "signet ring cells". Less common causes of ovarian metastasis are pancreaticobiliary tract cancers including cancers of the pancreas, gallbladder and bile ducts (cholangiocarcinoma), comprising roughly 6% of metastatic cancers to the ovary ([@bb0170]). However, mucinous metastases from the pancreaticobiliary tract often create diagnostic confusion as their histology and immunohistochemistry profiles are similar to that of primary mucinous ovarian carcinomas.

There are several case reports in the literature of mucinous ovarian neoplasms metastatic from the pancreaticobiliary tract that presented clinically as primary ovarian neoplasms ([@bb0170]; [@bb0160]; [@bb0005]; [@bb0010]; [@bb0015]; [@bb0020]; [@bb0025]; [@bb0030]; [@bb0035]; [@bb0045]; [@bb0050]; [@bb0055]; [@bb0060]; [@bb0075]; [@bb0070]; [@bb0065]; [@bb0080]; [@bb0085]; [@bb0090]; [@bb0095]; [@bb0100]; [@bb0105]; [@bb0110]; [@bb0120]; [@bb0130]; [@bb0135]; [@bb0150]; [@bb0185]; [@bb0190]; [@bb0195]; [@bb0205]; [@bb0210]; [@bb0215]; [@bb0220]; [@bb0240]; [@bb0245]; [@bb0155]). Many of these patients did not present with the typical symptoms of jaundice and back pain, but instead with vague symptoms often associated with ovarian malignancy (abdominal pain, abdominal-pelvic mass). The variable clinical presentations, radiologic findings, tumor serum markers and gross appearance of the ovarian neoplasms make an accurate histologic diagnosis essential to establish the treatment plan and prognosis. This review will highlight case reports and literature reviews that address the presentation and diagnosis of pancreaticobiliary metastases to the ovary compared to primary mucinous ovarian carcinomas. Our review will focus on the clinical and pathological features that help differentiate one from the other.

2. Materials and methods {#s0010}
========================

This systematic review was conducted in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement ([@bb0140]).

2.1. Search strategy {#s0015}
--------------------

A literature review of published literature on differentiating primary versus secondary mucinous ovarian neoplasms with a focus on ovarian metastases of pancreaticobiliary cancers was performed. Inclusion criteria included MeSH major terms "mucinous ovarian cancer", "panreaticobiliary tract cancer", "pancreatic", "bile duct", "gallbladder AND "neoplasm", "cancer", "metastases/metastasis". PubMed, Scopus, Embase, World Wide Science, and National Cancer Institute Grey Literature and Clinical trials were searched with the above stated criteria. All English-language articles published between 1985 and 2018 were included.

The electronic search identified 188 articles and 25 additional records found by manual search for a total of 213 articles ([Fig. 1](#f0005){ref-type="fig"}). After 55 duplicate articles were removed 158 articles remained. The articles were screened by title and abstract and 98 did not meet the inclusion criteria. The remaining 61 unique citations were further screened. Fifteen articles addressed a variety of metastatic cancers to the ovary and provided limited individual useful information about pancreaticobiliary carcinomas. These 15 articles were also excluded. Seven additional articles were removed due to inability to access the article and only non-English language versions of the article were available. Thirty-nine unique citations were selected for inclusion.Fig. 1PRISM diagram of article selection process ([@bb0140]).Fig. 1

2.2. Inclusion/exclusion criteria {#s0020}
---------------------------------

Inclusion was determined after review of article title and abstract, followed by full text review. If the full text was unavailable the article was excluded. Included articles were in the English language, involving human subjects, and published between 1985 and 2018. Included articles addressed a variety of features (as discussed within this review) used to facilitate the distinction of primary versus secondary ovarian neoplasms, specifically secondary mucinous carcinomas arising from the pancreaticobiliary tract. Exclusion criteria included articles with a primary focus on other sources of secondary mucinous carcinoma of the ovary including colon/rectum, appendix, stomach, breast and cervix. Articles were also excluded if they were primarily about treatment or management of the neoplasms and did not provide any contributing information to this review.

2.3. Data extraction {#s0025}
--------------------

For each included article information that could help in differentiating primary versus secondary mucinous ovarian carcinoma to include clinical presentation, gross and microscopic pathology findings, as well as immunohistochemistry staining profile was extracted.

Differences between primary mucinous ovarian and primary pancreaticobiliary groups were calculated using the independent group *t*-test for continuous variables and chi-squared for nominal variables. All statistical analysis was performed using IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.

3. Results {#s0030}
==========

The reported diagnosis from the cases extracted from the 39 articles reviewed included 394 primary mucinous ovarian carcinomas ([@bb0170]; [@bb0025]; [@bb0055]; [@bb0065]; [@bb0105]; [@bb0130]; [@bb0150]; [@bb0205]; [@bb0210]; [@bb0215]; [@bb0220]), 171 primary pancreatic carcinoma ([@bb0170]; [@bb0160]; [@bb0005]; [@bb0015]; [@bb0025]; [@bb0055]; [@bb0135]; [@bb0150]; [@bb0195]; [@bb0205]; [@bb0215]; [@bb0240]; [@bb0080]), 108 primary biliary tract carcinoma ([@bb0160]; [@bb0010]; [@bb0020]; [@bb0045]; [@bb0050]; [@bb0060]; [@bb0075]; [@bb0070]; [@bb0065]; [@bb0090]; [@bb0095]; [@bb0100]; [@bb0110]; [@bb0120]; [@bb0135]; [@bb0150]; [@bb0185]; [@bb0190]; [@bb0195]; [@bb0205]; [@bb0215]; [@bb0245]; [@bb0155]; [@bb0175]; [@bb0115]; [@bb0125]), and 48 unspecified pancreaticobiliary carcinoma ([@bb0030]; [@bb0135]; [@bb0210]; [@bb0220]; [@bb0155]). All tumors were classified as mucinous.

3.1. Clinical characteristics {#s0035}
-----------------------------

Primary mucinous ovarian tumors generally present with increasing abdominal girth, symptoms of abdominal distension which may be described as bloating abdominal pressure or pain, pelvic pressure or pain, changes in bowel or bladder habits, or other sequela of abdominal disease. [Table 1](#t0005){ref-type="table"} summarizes the reported clinical characteristics. The mean age of patients with primary ovarian mucinous carcinoma was 48.8 years compared to 54.2, 55.4, and 60.5 years for patients with primary pancreatic, primary biliary tract, or primary unspecified pancreaticobiliary cancer, respectively. Of those cases with case-specific data, 65.6% and 60.9% primary pancreatic and primary biliary tract carcinoma, respectively, presented with pelvic and/or abdominal pain. GI related symptoms were the presenting complaint in 25% of primary pancreatic and 23.4% of primary biliary tract carcinomas, while jaundice was the presenting symptoms in 15.6% in both groups. Other reported symptoms included pelvic mass/pressure, abdominal distention/ascites, vaginal bleeding, and weight loss.Table 1Clinical characteristics of women with primary mucinous ovarian carcinoma and those with ovarian metastasis from a pancreaticobiliary cancer.Table 1Primary mucinous ovarianPrimary pancreaticPrimary biliary tractPrimary pancreaticobilary (unspecified)Median age (range) (years)48 (18--78)54 (29--87)54 (33--80)65 (17--68)Presentation \[N and (%)\]NA32647Pelvic/Abdominal Pain21 (65.6)39 (60.9)1 (14.3)Abdominal Distention/ascites1 (3.1)9 (14.1)0Pelvic Mass3 (9.4)9 (14.1)1 (14.3)Vaginal Bleeding1 (3.1)3 (4.7)0Jaundice\
Weight Loss5 (15.6)10 (15.6)\
7 (20.9)0\
4 (57.1)GI Symptoms (RLQ pain, nausea, vomiting, epigastric pain, anorexia, obstruction)[a](#tf0005){ref-type="table-fn"}8 (25.0)15 (23.4)0Laboratory Values (mean, N)NANAAlkaline PhosphataseNP892 (14)[b](#tf0010){ref-type="table-fn"}Amylase45 (1)953 (1)CA 19--9337 (2)2360CA 12592 (5)(17)[c](#tf0015){ref-type="table-fn"}CEA13.1 (1)236 (24)[d](#tf0020){ref-type="table-fn"}\
N/A[^1][^2][^3][^4][^5]

Ovarian mucinous neoplasms are known to produce abnormal serum levels of certain substances. Carbohydrate antigen 19--9 or cancer antigen 19--9 (CA 19--9) is produced by mucin cells. It is commonly used in the evaluation of patients suspected to have exocrine pancreatic cancer with a reported sensitivity and specificity of 70--92% and 68--92%, respectively ([@bb0165]). The marker itself is a mucin protein. While mostly used to evaluate patients with pancreatic tumors, an elevated CA 19--9 level can also be found in cancers of other sites including liver, biliary, and GI tract, and in inflammatory conditions of those sites. Elevated levels have been reported in some primary ovarian mucinous tumors.

Serum cancer antigen 125 (CA 125) is a serum marker that has been associated with epithelial ovarian cancer. It is a mucin protein (MUC16) that is produced by mesoderm-derived cells and can be found in ovarian, pleural, peritoneal, and pericardial cells ([@bb0225]; [@bb0040]). Due to its widespread production and presence in these epithelia, CA 125 provides limited value in the context of cancer, as inflammation or irritation of these epithelial surfaces can produce elevated levels.

Our review includes limited data on serum tumor markers as many of the available articles did not include this information. In patients with primary pancreatic carcinoma levels of CA 19--9 ranging from 20 to 654 U/mL were reported, while reported CA 125 levels ranged from 90 to 98 U/mL. In patients with primary biliary tract very elevated levels of alkaline phosphatase (mean 892 IU/L, range 128--2, 620 IU/L), CA 19--9 (mean 2360 U/mL, range 119--30,000 U/mL) and CA 125 (mean 236 U/mL, range 9--730 U/mL) were reported. Elevated levels of alkaline phosphatase and significantly high levels of CA 19--9 may be useful in differentiating primary ovarian mucinous carcinoma from metastatic pancreaticobiliary cancer.

3.2. Gross characteristics {#s0040}
--------------------------

[Table 2](#t0010){ref-type="table"} summarizes the gross characteristics of the various cancers reviewed. Primary ovarian mucinous tumors were largely unilateral (3/107, 96.3%), cystic in appearance (25/28, 89.3%), with solid components (21/28, 75%), had a smooth surface (20/25, 80%) without surface implants (43/44, 97.7%), and were larger in size (mean 20.3 cm) when compared to metastatic tumors. The majority of pancreaticobiliary tumors metastatic to the ovaries were bilateral, cystic with solid components, with tumor surface implants, and without a smooth appearing surface.Table 2Gross characteristics of primary ovarian mucinous tumors and pancreaticobiliary carcinoma metastatic to the ovaries.Table 2Proportion N (%), Mean/rangePrimary Ovarian MucinousPrimary PancreaticPrimary Biliary TractPrimary Pancreaticobiliary (unspecified)*P*-value (primary v. metastatic)Bilateral4/108\
(3.7)42/47\
(89.4)62/79\
(78.5)24/31\
(77.4)\<0.001Cystic Appearance25/28\
(89.3)11/13\
(84.6)58/69\
(84.1)NA0.757NodularityNA16/28\
(57.1)22/49\
(44.9)3/6\
(50)NPSize (cm, range)20.3\
(5--48)9.2\
(1.5--22)10.0\
(0.22--22.0)9.8\
(2.5--21)\<0.001Smooth Surface20/25\
(80.0)7/27\
(25.9)15/64\
(23.4)NA\<0.001Solid Components21/28\
(75.0)6/6\
(100)54/67\
(80.6)NA0.417Surface Implants1/44\
(2.3)26/33\
(78.8)45/64\
(70.3)2/3\
(66.7)\<0.001[^6][^7]

3.3. Histology {#s0045}
--------------

A summary of the histological characteristics described in the articles reviewed are included in [Table 3](#t0015){ref-type="table"}. Compared to primary ovarian mucinous tumors, pancreaticobiliary carcinoma metastatic to the ovary exhibits a higher proportion of infiltrative histologic pattern (*p* \< .001) and a higher rate of signet ring cell presence, particularly in biliary tract tumors (p \< .001). Some of the articles reported histologic involvement of the ovarian hilum for primary ovarian and biliary tract cases, of which a higher proportion of hilum involvement was noted in biliary tract tumors (42.3% versus 2.4%, p \< .001).Table 3Histologic findings of primary mucinous ovarian carcinoma and pancreaticobiliary carcinoma metastatic to the ovary.Table 3Proportion N (%)Primary Ovarian MucinousPrimary PancreaticPrimary Biliary TractPrimary Pancreaticobiliary (unspecified)p-value (primary vs. metastatic)Infiltrative Pattern5/41\
(12.2)26/40\
(65.0)44/59\
(74.6)5/7\
(71.4)\<0.001Involvement of Ovarian Hilum1/41\
(2.4)NA22/52\
(42.3)NA\<0.001Signet Ring Cells3/108\
(2.8)2/28\
(7.1)9/28\
(32.1)1/20\
(5.0)0.001[^8]

3.4. Immunohistochemistry {#s0050}
-------------------------

Immunostains have been extensively studied in the distinction between primary and secondary mucinous ovarian neoplasms. Cytokeratin (CK) 7 and CK20 are most frequently helpful in distinguishing between colorectal (CK7^−^/CK20^+^) and ovarian primaries (CK7^+^/CK20^−^ or CK20^+^) ([@bb0075]; [@bb0070]; [@bb0065]). CK7 is typically diffusely positive in primary ovarian mucinous carcinomas, while CK20 shows variable positivity ([@bb0200]). [Table 4](#t0020){ref-type="table"} lists the summary of immunostaining reported in studies reviewed. CK7 was positive in a majority of both primary ovarian mucinous and pancreaticobiliary tumors metastatic to the ovaries. MUC1 can be helpful in differentiating primary ovarian mucinous from metastatic pancreaticobiliary as our review found only 19.4% of primary ovarian mucinous carcinomas stained positive, while \>90% of biliary tract and 100% of pancreatic tumors metastatic to the ovaries stained positive. MUC5AC was found to stain a high proportion of ovarian mucinous carcinomas and pancreatic carcinomas metastatic to the ovaries, but not metastatic biliary carcinomas (97.8 and 93.3% versus 16.7%, respectively). Although limited in number of cases, staining for CDX2 was more common in metastatic pancreaticobiliary tumors compared to primary ovarian mucinous carcinomas (64.3% versus 37.8%).Table 4Immunohistochemistry staining pattern of primary mucinous ovarian carcinoma and pancreaticobiliary carcinoma metastatic to the ovaries.Table 4Proportion N (%)CK7CK20CK17CEAMUC1MUC5ACDPC4CDX2Other (n/%)Primary Mucinous ovarian195/199 (98.0)123/167 (73.7)NA8/15\
(53.3)7/36 (19.4)91/93 (97.8)NA17/45\
(37.8)CA125\
5/15 (33.3)\
WT1\
0/12 (0)Primary pancreatic35/38 (92.1)46/102 (45.1)27/64 (42.2)58/72 (81.2)18/18 (100)28/30 (93.3)16/34\
(47.1)NACA125\
52/64\
(81.3)Primary Biliary Tract25/30\
(83.3)17/30\
(56.7)NANA11/12\
(91.7)2/12\
(16.7)3/4\
(75)1/4\
(25.0)CA19--9\
1/1 (100)Primary pancreaticobiliary (unspecified)3/3 (100)15/17 (88.2)NANANANA0/7\
(0.0)9/15\
(60.0)[^9]

4. Discussion {#s0055}
=============

Our review highlights features that could be used in distinguishing primary ovarian mucinous carcinoma from pancreaticobiliary carcinomas metastatic to the ovary. Laterality and size were notably different between primary ovarian mucinous metastatic pancreaticobiliary tumors ([Table 2](#t0010){ref-type="table"}). Pancreaticobiliary carcinomas metastatic to the ovary are more frequently bilateral and smaller than 10 cm. Gross appearance was also different in primary ovarian mucinous and metastatic pancreaticobiliary tumors. The surface of the primary mucinous ovarian tumors are most often smooth and contain no surface implants, while ovarian tumors due to metastasis from pancreaticobiliary carcinoma most often have an irregular surface and surface implants. The presence of cystic and solid components was not found to be different between primary and secondary neoplasms.

Our results are consistent with other reports on differences between primary and metastatic ovarian mucinous carcinomas. Dr. Robert H Young produced the first report and a detailed review on metastatic tumors to the ovary in which he highlighted the mimicry of primary mucinous ovarian tumors by metastases ([@bb0230]; [@bb0235]). In this review he notes that the clinical presentation of primary versus secondary mucinous ovarian tumors can be variable, and many times the secondary ovarian neoplasm may present similar to the presentation of a primary neoplasm. Similarly, our study reported abdominal and pelvic pain as the most frequent symptom with secondary ovarian neoplasms, with variable GI complaints as the second. It is worth noting that secondary neoplasms of the ovary are often larger than their corresponding primary tumors in GI sites. Their large size is often responsible for a patient\'s initial clinical presentation and may contribute to misdiagnosis as an ovarian primary. The first paper to highlight this mimicry from GI sites other than the appendix and intestines, began with Dr. Young\'s own series on pancreatic primaries ([@bb0240]).

Since then, various diagnostic algorithms involving tumor size and laterality have been created to help clinically differentiate between primary and metastatic tumors, often at the time of surgery. ([@bb0170]; [@bb0050]; [@bb0045]) In 2003 Seidman et al. published the first algorithm based on size and laterality of ovarian neoplasms that correctly classified 90% of mucinous ovarian carcinomas in their series. In effect, bilateral tumors suggested metastases and unilateral tumors \>10 cm favored primary tumors ([@bb0170]). In 2006, Khunamornpong sought to further validate this algorithm and used it to classify 74 cases of mucinous adenocarcinomas with 84% correctly classified. Bilaterality and size \<10 cm remained the strongest predictors of ovarian involvement with metastasis. However, they concluded that "the prediction of primary mucinous adenocarcinomas by unilaterality and size 10 cm or greater was less reliable than previously reported" ([@bb0065]). Yemelyanova et al. analyzed series of 194 mucinous tumors (52 primary, 142 metastases) and optimized the size standard to be \>13 cm to identify primary tumors which resulted in a correct classification of 87% of tumors overall (98% of primary tumors, 82% of metastases). In their series 20 metastatic mucinous tumors were derived from the pancreaticobiliary tract and this algorithm correctly classified 100% of them ([@bb0220]). More recently, Simons et al. used similar characteristics to improve the sensitivity of an algorithm. In addition to laterality and size, they found that patient age and tumor histology (signet ring) were important components to increase sensitivity in classifying primary ovarian versus metastatic mucinous carcinomas ([@bb0180]).

We identified an infiltrative pattern as being more often seen in secondary ovarian tumors from pancreaticobiliary metastasis. Signet ring cells and hilar involvement are rarely seen in primary ovarian mucinous carcinomas ([Table 3](#t0015){ref-type="table"}).

Lee and Young provided a useful summary of histologic features after reviewing a series of 50 mucinous ovarian tumors (25 primary, 25 metastatic). They concluded that surface involvement by tumor cells, extensive extraovarian tumor, an infiltrative and nodular pattern of invasion, and the presence of signet ring cells are all features that favor metastases. Histologic features favoring primary ovarian neoplasms include an expansive (pushing) pattern of invasion, and a complex papillary pattern ([@bb0105]). It is important to note that this review included metastatic mucinous tumors from a variety of sites, not just the pancreaticobiliary tract.

Meriden et al. reviewed 35 cases of ovarian metastases from pancreaticobiliary tract adenocarcinomas found in the literature and summarized their findings ([@bb0135]). In this series, surface involvement (40%) was not as prominent of a distinguishing feature of secondary tumors due to metastasis compared with nodular growth pattern (63%). The presence of tumor foci in the hilar region of the ovary was common and suggestive of metastases. This emphasizes the importance of adequate hilar tissue sampling if metastasis to the ovary is suspected.

Our review showed that immunohistochemical staining with MUC1 is the most helpful stain that could help differentiate mucinous carcinoma form pancreaticobilary metastasis to the ovary from primary mucinous ovarian carcinoma ([Table 4](#t0020){ref-type="table"}).

Goldstein et al. evaluated additional immunostain panels including Wilm\'s tumor 1 (WT1), CK17, CK20, carcinoembryonic antigen (CEA), and CA-125 in pancreaticobiliary adenocarcinomas versus ovarian serous carcinomas versus primary ovarian mucinous neoplasms. Their results primarily distinguish ovarian serous carcinomas from the others. Of the ovarian serous carcinomas reviewed, 38 (93%) of 41 were reactive for WT1. In contrast, both metastatic pancreaticobiliary adenocarcinomas and primary mucinous ovarian cancers were WT1 negative. Interestingly this study identified a different potential marker for pancreaticobiliary carcinoma, CK17. In their study 27% of metastatic pancreaticobiliary carcinomas had immunoreactivity to CK17. Our study reported 42.2% CK17 immunoreactivity which is similar to other studies who report 42--83% CK17 immunoreactivity in cases of metastatic pancreatobiliary carcinoma. This is in stark contrast to primary mucinous ovarian cancers that exhibit no CK17 immunoreactivity ([@bb0025]). Immunohistochemical expression of DPC4 (deleted pancreatic carcinoma 4) was retained in 98% of primary ovarian mucinous tumors compared with only 45% to 50% of bile duct carcinomas ([@bb0055]). However, it is important to note that DPC4 expression is variable along the biliary tract; in pancreatic carcinoma only approximately 55% of tumor exhibits loss of DPC4 expression, limiting its use. The value of CK17 staining in the differential diagnosis of metastatic pancreaticobiliary carcinomas and primary mucinous ovarian carcinomas deserves further investigation as this marker is not widely used.

To our knowledge our study is the largest review of pancreaticobiliary tumors. Our study is however limited by exclusion criteria which excluded non-English studies as reviewers primary language is English and studies which analyzed metastatic subtypes as a group versus individually. Additionally, the study was limited by the inability to examine original samples. Our data was derived from each respective study and was therefore limited to the published data.

Metastatic mucinous carcinomas to the ovary mimic their primary mucinous ovarian counterparts and their clinical and histopathological features overlap in many ways. We reviewed the literature and found many distinctive clinical and pathological features that may help clinicians and pathologists decipher primary versus metastatic lesions of the ovary. Of those highlighted, for metastatic tumors to the ovary, our review continues to endorse bilaterality, size \<10 cm, and involvement of the ovarian hilum and adds other defining features including the presence of surface irregularity (implants and texture), infiltrative pattern, and identification of signet ring cells. Additionally, the use of immunostains (CK17, MUC1) could help in making the correct diagnosis.

Clinicians who encounter the patient who presents with a large ovarian mass or masses should maintain a high index of suspicion for the possibility of metastatic carcinoma to the ovary. Thorough abdominal exploration and tissue sampling at the time of surgery could identify an occult non-ovarian cancer that presents as a secondary ovarian neoplasm.
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[^1]: NA = data not available

[^2]: 1 case each of large bowel obstruction, rectal bleeding, 2 cases of epigastric pain

[^3]: all but 1 value elevated above 137 IU/L

[^4]: 2 cases of outliers- 1 value of 20,000, one value of 30,000; 16 of 17 values elevated above 37 U/ml

[^5]: 3 of 27 cases with reported normal levels

[^6]: NA = data not available
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